[ad_1]
The Food and Drug Administration will promote the unification of the authorization of injections of oxycodone hydrochloride components
The Ministry of Health and Welfare (KFDA) announced on 27 that the unilateral administration of oxycodone hydrochloride single agent (injection)
In the unification coordination proposal, the first warning is that the combination of narcotics and benzodiazepines or depressants of the Central nervous system, including alcohol, can cause deep sedation, respiratory depression, coma and death.
Because of this danger, the combined use of drugs and benzodiazepines should only be prescribed to patients who do not have appropriate alternative treatment methods, and if the combination of oxycodone and medication is decided, prescribe, and for the signs and symptoms of respiratory depression and sedation. It has been suggested that opioid agonists such as oxycodone may affect the hypothalamic-pituitary-adrenal (HPA) axis or the hypothalamic-pituitary-gonadal (HPG) axis.
and
Elements of interaction include benzodiazepines, other narcotic badgesics, general anesthetics, phenothiazine-based drugs, concomitant use of drugs, nerve stabilizers, of sleeping pills, cardiovascular antidepressants, neuromuscular blocking agents and other central nervous system inhibitors, including alcohol, causes additional inhibitory action of the central nervous system and is badociated with the system. central nervous system: respiratory depression, hypotension, deep sedation or coma,
Therefore, when the drug is administered concomitantly with these drugs, the administration of two drugs Both should be considered for dosing and should be prescribed during the shortest period with the lowest effective dose if oxycodone and concomitant use of hibitors of the central nervous system are necessary and careful monitoring of the signs and symptoms of respiratory depression and sedation
In addition, it is indicated that the combination of oxycodone with anticholinergic or anticholinergic drugs may increase the side effects anticholinergics.
Contents related to CYP3A4 and CYP2D6 of the existing license are also modified.
Oxycodone is metabolized mainly by CYP3A4 and partially metabolized by CYP2D6 The activity of these metabolic pathways may be inhibited or induced by various drugs or dietary components coadministered,
Antibiotics microlids, antifungal agents azoles, protease inhibitors Inhibitors of CYP3A4 such as ciprofloxacin, cimetidine and grapefruit juice may reduce the clearance rate of oxycodone and cause an increase in the plasma concentration of oxycodone, and the CYP3A4 inducers such as rifampicin, carbamazepine, phenytoin, and St. John's wort may increase the clearance rate of oxycodone,
Drugs that inhibit the activity of CYP2D6, such as paroxetine and quinidine , may decrease the rate of clearance of oxycodone and lead to an increase in the plasma concentration of oxycodone.
< 저작권자 © 의약뉴스 무단전재 및 재배포금지 >
Included were items that were injected by Hana Pharmaceutical Co., Ltd.
< 저작권자 © 의약뉴스 무단전재 및 재배포금지 >
